Article
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Journal of acquired immune deficiency syndromes (1999) - 1 Oct 2009
Margot Nicolas A, Enejosa Jeff, Cheng Andrew K, Miller Michael D, McColl Damian J
Abstract excerpt
Study 934 was an open-label, randomized Phase III study of emtricitabine + tenofovir DF + efavirenz (FTC + TDF + EFV) compared with lamivudine + zidovudine + efavirenz (3TC + ZDV + EFV) in antiretroviral therapy-naïve HIV-1 infected subjects. Baseline genotyping revealed the presence of primary n...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
